Walk into any med spa in 2026 and you will hear a wall of proper nouns deployed with total confidence: Moxi, Clear + Brilliant, Halo, UltraClear, picosecond, RF microneedling. The words alone are supposed to signal expertise. They do not explain what is actually happening to your face. Here is what the physics, the published studies, and the dermatologists on record are actually saying, separated from what the consultation-room script wants you to believe.
The naming problem is the marketing problem
"Fractional" simply means a device fires energy in a grid of microscopic columns instead of covering the whole surface, leaving untouched skin between treated zones so healing happens faster. That is the entire definition. It is not a brand, not a luxury tier, not a guarantee of results. Clear + Brilliant has been marketed for over a decade as "Baby Fraxel," a nickname invented in treatment rooms, not a clinical classification, and it sits in the same functional category as Moxi, Solta's newer nonablative pico-fractional device: energy mild enough to carry close to zero real downtime, aimed at early photodamage, faint texture, and maintenance, not at deep wrinkles, acne scarring, or lax skin. Patients who need heavier correction get steered toward Halo, a hybrid platform blending ablative and nonablative wavelengths in one pass, traditional fractional CO2 or Er:YAG resurfacing, or a Fraxel Dual treatment dialed to higher energy. Same manufacturer family in some cases, an entirely different clinical job.
The point dermatologists keep making, and marketing keeps burying, is that outcomes depend on settings, technique, and the person holding the handpiece, not the platform's name recognition. A Clear + Brilliant session run at low energy by an inexperienced provider will do less for your skin than a well-executed IPL treatment. The device name is not the variable that matters most.
What is actually new this year
Two things circulating in 2026 aesthetic dermatology are worth knowing by name because they represent real engineering or clinical-protocol changes, not rebrands with new marketing decks.
- UltraClear (Acclaro), a 2910 nm fiber laser — marketed as the first "cold ablative" fiber laser, using a fiber-delivery system and pulsing pattern engineered to ablate tissue with less collateral thermal spread than a standard CO2 or Er:YAG unit. It drew presentations at the 2026 American Academy of Dermatology annual meeting specifically on that collateral-damage question, which is the one that actually determines your downtime and your hyperpigmentation risk, not the marketing copy.
- RF microneedling paired with picosecond lasers — not a single device but a combination protocol now backed by real published data. A study combining radiofrequency microneedling with a 755 nm picosecond laser using a fractionated lens array reported 100% of subjects showing clinical improvement on the treating physician's global aesthetic assessment scale, with 88.9% of subjects satisfied. That is an actual clinical outcome, not a spa brochure claim.
Skin tone is not a footnote, it is the deciding variable
Here is the fact most marketing copy flattens into nothing: RF microneedling's mechanism does not target melanin at all. It delivers thermal energy through mechanical needle penetration, which is why it carries meaningfully lower risk of post-inflammatory hyperpigmentation in deeper skin tones. Picosecond and Q-switched lasers, by contrast, work by targeting pigment directly, which is exactly why they are effective for dyspigmentation and exactly why they carry real hyperpigmentation risk in the wrong hands or the wrong settings on darker skin. Neither device is better in the abstract. They solve different problems through different physics, and the right choice depends on Fitzpatrick skin type and the specific concern being treated, not on which platform photographs better.
The right choice depends on your unique skin profile, your concerns, and your recovery tolerance, not on which platform has the better name.
The risks nobody writes on the consultation-room whiteboard
Every ablative or fractional device on this list can burn, scar, or leave lasting discoloration when energy settings exceed what a given skin type can safely handle. The real risks are specific: post-inflammatory hyperpigmentation is the most common complication, especially in Fitzpatrick IV through VI skin treated too aggressively; textural scarring can follow over-aggressive CO2 settings; prolonged erythema is common after deeper treatments; and actual burns happen when an undertrained operator runs a device outside its safe parameters. True ablative CO2 or deep Er:YAG resurfacing carries five to ten days of visible healing, not the "zero downtime" language med spas now attach to nearly everything on the menu. Cost varies as widely as the marketing: a single Clear + Brilliant or Moxi session typically runs $400 to $800; a full-face CO2 or Halo treatment commonly runs $1,500 to $3,000 per session, frequently requiring more than one to see the promised result.
None of this is a reason to avoid these devices. The clinical evidence behind fractional resurfacing, RF microneedling, and picosecond lasers is real and still growing. It is a reason to get your consultation from a board-certified dermatologist or a physician-supervised practice rather than a med spa price list, before anyone points a handpiece at your face. Ask what wavelength, what energy setting, and why for your skin specifically, not why for the device's marketing copy.
